<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151723</url>
  </required_header>
  <id_info>
    <org_study_id>SUBstudie</org_study_id>
    <nct_id>NCT00151723</nct_id>
  </id_info>
  <brief_title>Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?</brief_title>
  <official_title>Subclinical Hyperthyroidism &quot;To Treat or Not to Treat?&quot; A Dutch Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Subclinical hyperthyroidism is defined as the presence of serum free thyroxine (T4) and&#xD;
      triiodothyronine (T3) levels within the reference range and a reduced serum thyrotrophin&#xD;
      (TSH) level. Evidence is accumulating that it has important clinical effects. The SUBstudy is&#xD;
      a randomised, Dutch multicenter trial to study whether radioiodine treatment prevents the&#xD;
      development of atrial fibrillation and prevents decreases in bone mineral density in patients&#xD;
      with endogenous subclinical hyperthyroidism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide evidence that restoration of euthyroidism (normal TSH) improves thyrotoxic symptoms and signs and quality of life and lowers the risk of subsequent atrial fibrillation and bone loss in subjects with endogenous subclinical hyperthyroidism</measure>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperthyroidism</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>treatment with 131I</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subclinical hyperthyroidism [TSH â‰¤ 0.1 mU/L, fT4 and T3 within the normal range of the&#xD;
             own laboratory (determined 2 times in own laboratory) with an interval of at least 2&#xD;
             months].&#xD;
&#xD;
          -  Endogenous cause of subclinical hyperthyroidism limited to autonomous adenoma or&#xD;
             multinodular goiter (diagnosis made by the attending physician, based on palpation and&#xD;
             the result of a thyroid scintigram).&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medication with anti-thyroid drugs in the last 3 months (also not allowed during&#xD;
             follow-up); thyroid hormone in the last 3 months (allowed during follow-up, but TSH&#xD;
             levels should be kept between 0.1 mU/L and the upper limit of normal in the own&#xD;
             laboratory); and oral glucocorticoids in the last 3 months (allowed during follow-up&#xD;
             when absolutely necessary, but patients in whom glucocorticoids are started cannot be&#xD;
             evaluated with respect to changes in bone mineral density [BMD]).&#xD;
&#xD;
          -  Radioiodine therapy in the past.&#xD;
&#xD;
          -  Iodine-induced subclinical hyperthyroidism.&#xD;
&#xD;
          -  Pituitary or hypothalamic insufficiency.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Age &lt;= 40 years.&#xD;
&#xD;
          -  Severe non-thyroidal illness.&#xD;
&#xD;
          -  Drug abuse.&#xD;
&#xD;
          -  Unstable angina pectoris, (history of) atrial fibrillation, (history of) congestive&#xD;
             heart failure.&#xD;
&#xD;
          -  (History of) osteoporotic fracture(s).&#xD;
&#xD;
          -  Patients younger than 70 years of age with a bone mineral density T-score &lt; - 2.5&#xD;
             standard deviations (SD), or older than 70 years of age with a bone mineral density&#xD;
             Z-score &lt; 1.0 SD. (These patients can be randomized but in case it is decided to treat&#xD;
             them with anti-osteoporotic drugs they cannot be evaluated with respect to changes in&#xD;
             BMD.)&#xD;
&#xD;
          -  Use of betablockers in the last three months. (These patients can be randomised but&#xD;
             cannot be evaluated with respect to general and cardiac symptoms. The same applies to&#xD;
             patients in whom betablockers are started during follow up.)&#xD;
&#xD;
          -  Other symptoms or signs of hyperthyroidism or obstruction of vital structures which,&#xD;
             in the opinion of the attending physician, require active treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad Hermus, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Hoogendoorn, MD</last_name>
    <phone>++31243614599</phone>
    <email>e.hoogendoorn@endo.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ad Hermus, MD, Prof</last_name>
    <phone>++31243614599</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academical Medical Centre Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Wiersinga, MD, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. van Tol, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>K. van Tol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. van den Berg, MD, PhD</last_name>
      <phone>++31-5036161616</phone>
    </contact>
    <investigator>
      <last_name>G. van den Berg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hoogendoorn, MD</last_name>
      <phone>++31-243614599</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Hoogendoorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Haak, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>H. Haak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Hoogendoorn EH, Wiersinga WM, Prummel MF, den Heijer M, Corstens FH, Hermus AR. [Subclinical hypothyroidism; the start of a clinical trial into the usefulness of treatment with radioactive iodine]. Ned Tijdschr Geneeskd. 2004 May 8;148(19):953-4. Review. Dutch.</citation>
    <PMID>15160563</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 17, 2007</last_update_submitted>
  <last_update_submitted_qc>July 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2007</last_update_posted>
  <keyword>endogenous subclinical hyperthyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

